Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.
Valuation & Earnings
This table compares Vivos Therapeutics and Tandem Diabetes Care”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.10 | -$21.17 million | ($1.90) | -0.05 |
| Tandem Diabetes Care | $1.01 billion | 1.29 | -$204.71 million | ($0.72) | -25.99 |
Vivos Therapeutics has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Vivos Therapeutics has a beta of 6.37, meaning that its share price is 537% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Profitability
This table compares Vivos Therapeutics and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Tandem Diabetes Care | -4.58% | -35.61% | -4.53% |
Institutional and Insider Ownership
26.4% of Vivos Therapeutics shares are owned by institutional investors. 1.4% of Vivos Therapeutics shares are owned by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Vivos Therapeutics and Tandem Diabetes Care, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Tandem Diabetes Care | 1 | 12 | 9 | 1 | 2.43 |
Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 3,144.50%. Tandem Diabetes Care has a consensus price target of $27.18, indicating a potential upside of 45.29%. Given Vivos Therapeutics’ higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than Tandem Diabetes Care.
Summary
Tandem Diabetes Care beats Vivos Therapeutics on 10 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
About Tandem Diabetes Care
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
